Abstract 5113
Background
BioRAIDs is a supervised longitudinal collection of tumor and blood together with clinical outcome data in 419 primary cervical cancer patients from 7 European countries (NCT02428842).
Methods
Molecular analysis [Next Generation Sequencing (NGS) at SeqOmics (Hungary) & Reverse Phase Protein array (RPPA) at Institut Curie] was performed on quality-controlled primary tumor samples in 295 patients (70%) who subsequently had received primary radio chemotherapy (RCT). Integrative bioinformatics analyses were performed to identify pathway activations suggesting the need for additional/different therapies.
Results
NGS demonstrated driver Tyrosine Kinase Receptor/ PI3 kinase (TKR/PI3K) pathway mutations in 27%; TKR/PI3K + epigenetic pathway alterations (MLL2, MLL3) in 32 % and epigenetic alterations alone in 13% of patients. At a median follow up of 19 months [2-38], tumors for which no mutations in relevant genes from the TKR/PI3K pathways nor alterations in genes involved in epigenetic signaling appeared to be associated with a significantly better prognostic profile: HR = 2.4 [95% CI: 1.1 – 5.2]. RPPA analysis was carried out separating patients in 3 subgroups according to signaling pathway activation [EMT (epithelial mesenchymal transition), DNA damage and MAPK/PI3K], none of which was associated with bad prognosis.
Conclusions
The high frequency of epigenetic alterations with or without TKR/PI3K pathway mutations, suggests that epigenetically acting drugs (VorinostatR) may be relevant for patients whose tumors have genetic mutations of significance in epigenetically acting enzymes. Relevance of copy number alterations and of other frequently mutated genes (CSMD3, SYNE1), needs to be integrated and cross validated in a larger complementary dataset.
Clinical trial identification
NCT02428842.
Legal entity responsible for the study
Institut Curie.
Funding
This project has received founding from the European Union’s Seventh Program for research, technological development and demonstration under grant agreement No 304810.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2060 - Relationship between ring-type dedicated breast PET and tumor-infiltrating lymphocytes in early breast cancer
Presenter: Shinsuke Sasada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2070 - Short-term responders of non-small cell lung cancer patients to EGFR tyrosine kinase inhibitors display high prevalence of TP53 mutations and primary resistance mechanisms
Presenter: Yun Fan
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2130 - Assessment of cfDNA in patients with metastatic colorectal cancer treated with cetuximab monotherapy
Presenter: Lindsay Angus
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2446 - Quantifying circulating cell-free DNA as clinical biomarker
Presenter: MEDDEB Romain
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2958 - Gene Expression Profile (GEP) and Survival Among Patients With Advanced Ovarian Cancer
Presenter: Estrid Høgdall
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3621 - Predicting survival benefit of capecitabine plus cisplatin in patients with metastatic gastric cancer patients using quantitative proteomics.
Presenter: Dongyao Yan
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3634 - Detection of microsatellite instability (MSI) with a novel set of 7 Idylla biomarkers on colorectal cancer samples in a multi-center study
Presenter: Bram De Craene
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3748 - Accurate measurement of tumor mutation burden in liquid biopsy (bTMB) using a 500 gene panel
Presenter: Tingting Jiang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3753 - Circulating tumor DNA and RNA as an exploratory biomarker to evaluate GT0918 in a Phase 1/II clinical trial in mCRPC patients
Presenter: Mengyao Tan
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5062 - The frequency of primary cilia, CD8+ tumor infiltrating lymphocytes and PD-1 expression in renal cell carcinoma of clear-cell type
Presenter: Josef Dvorak
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract